Published Date: 07 Feb 2024
Among older patients, pulmonary malignancy is one of the most common and deadly cancers. Research has demonstrated that lower respiratory tract infections are common in patients with lung cancer. This is because of the circumstances.
Read Full NewsIn a new trial, patients with PD-L1 CPS ≥ 1 HNSCC were randomly assigned 1:1 to receive 20 mg/d lenvatinib orally plus pembrolizumab 200 mg intravenously or placebo orally once daily plus pembrolizumab 200 mg intravenously.
The agency also granted traditional approval to later-line nivolumab indications for certain adults with the disease.
1.
Novel probes to label macrophages associated with cancer progression using a selective dye
2.
Chronic stress and obesity work together to accelerate pancreatic cancer development and growth, study finds
3.
Most women with early-stage breast cancer can anticipate living long lives, according to experts.
4.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
5.
Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.
1.
Mechanistic Insights into Abraxane, Verzenio, and the Management of Chemotherapy-Induced Tachycardia
2.
Unveiling the Mystery Behind Castleman Disease – Understanding Its Causes and Symptoms
3.
Tazemetostat: A Promising New Treatment for Cancer
4.
CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma: A Comprehensive Review
5.
Understanding Lymphedema: Symptoms, Causes, and Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
2.
Should We Use DARA Up Front As First-Line Therapy in MM?
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
5.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation